Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Rilpivirine LA Nanosuspensions with Different Particle Sizes
NCT03127189Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilpivirine in human immunodeficiency virus infection (HIV) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Session 2: Maximum Observed Plasma Concentration (Cmax) at 6048 hours, Session 2: Area Under the Plasma Concentration-Time Curve From Time Zero (Day 1) to Day 28 (AUC[0-d28]) and 2 more. Started Apr 2017; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03127189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127189.